

Provider Update

Part B updates for Praluent, Repatha and Sylvant

The following three new injectable drugs are being added to the 2016 Medicare Advantage list of Part B Injectables/Infusibles requiring prior authorization. **As of January 1, 2016, providers must call for prior authorization of these drugs:**

1. Praluent (alirocumab): used to reduce serum low-density lipoprotein cholesterol (LDL-C)
 - a. Unlisted, no J code established for the precertification list at this time
2. Repatha (evolocumab): used to reduce serum low-density lipoprotein cholesterol (LDL-C)
 - a. Unlisted, no J code established for the precertification list at this time
3. Sylvant (siltuxumab): for treatment of Multicentric Castleman's disease (MCD)
 - a. Code C9455

Please note that Praluent and Repatha are currently billed under the not otherwise classified (NOC) J codes J3490 and J3590, and Sylvant is using code C9455. Since these codes include all drugs NOC, the plan's denial will be for the drug and not the HCPCS.

This update to the 2016 prior authorization requirement applies to all of Amerigroup's Medicare Advantage plans.

55856WPSNMUB 09/11/15

Amerivantage is a DSNP plan with a Medicare contract and a contract with the State Medicaid program. In New Mexico: Amerivantage is an HMO with a Medicare contract. Enrollment in Amerivantage depends on contract renewal.

*In New Mexico, Amerigroup Community Care of New Mexico, Inc. In Texas, Amerigroup members in the Medicaid Rural Service Area are served by Amerigroup Insurance Company; all other Amerigroup members are served by Amerigroup, Texas, Inc. In Washington, Amerigroup Washington, Inc.

WEB-SSO-0067-15
Issued September 2015
by Amerigroup Specialty Products Group

